CHINA’S CAS COVID-19 VACINE INDUCES IMMUNE RESPONSE IN MID STAGE TESTS
Researchers said a COVID-19 vaccine candidate developed by the Chinese Academy of Science (CAS) was found to be safe and triggered immune responses in early and mid-stage trials.
A late-stage trial of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products, began last month in China.
It aims to recruit 29,000 people across China, Uzbekistan, Indonesia, Pakistan and Ecuador.
The candidate did not cause serious adverse events, with common mild side-effects including injection pain, redness and swelling, researchers at the Chongqing Zhifei unit, CAS, and other Chinese institutes said in a paper published on Tuesday ahead of peer review.
The combined data from Phase 1 and 2 trials involved 950 healthy Chinese participants aged 18-59.
Low dose and high dose versions were tested, and the Phase 2 study also tested two doses versus three doses for both the low dose and high dose versions.